EADV Congress 2025: GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients

Contributed by: PR Newswire

Tags

EADV-Congress-2025

More Like This

PR Newswire associated0

GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

Two in Three Patients Hide Weight Loss Treatment, UK Study Finds

EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows

PR Newswire associated0

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks